Analysts Offer Predictions for Nuvectis Pharma Q1 Earnings

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Roth Capital issued their Q1 2025 earnings per share estimates for Nuvectis Pharma in a note issued to investors on Tuesday, November 5th. Roth Capital analyst J. Aschoff anticipates that the company will post earnings per share of ($0.23) for the quarter. The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.05) per share. Roth Capital also issued estimates for Nuvectis Pharma’s Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.23) EPS and FY2028 earnings at $3.61 EPS.

Nuvectis Pharma (NASDAQ:NVCT) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.01. During the same quarter in the prior year, the business posted ($0.37) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $21.00 price objective on shares of Nuvectis Pharma in a research note on Tuesday, August 6th.

Nuvectis Pharma Stock Performance

NVCT opened at $8.15 on Wednesday. The firm’s fifty day moving average is $6.81 and its two-hundred day moving average is $6.68. The firm has a market cap of $152.00 million, a PE ratio of -6.32 and a beta of 0.41. Nuvectis Pharma has a twelve month low of $5.85 and a twelve month high of $12.10.

Hedge Funds Weigh In On Nuvectis Pharma

Several institutional investors have recently modified their holdings of NVCT. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Nuvectis Pharma during the 2nd quarter worth approximately $58,000. Nations Financial Group Inc. IA ADV acquired a new stake in shares of Nuvectis Pharma during the third quarter worth $63,000. Baxter Bros Inc. acquired a new stake in shares of Nuvectis Pharma during the second quarter worth $79,000. GSA Capital Partners LLP lifted its position in Nuvectis Pharma by 3.7% in the 3rd quarter. GSA Capital Partners LLP now owns 50,129 shares of the company’s stock valued at $315,000 after acquiring an additional 1,790 shares in the last quarter. Finally, Iridian Asset Management LLC CT acquired a new position in Nuvectis Pharma in the 3rd quarter worth $348,000. Institutional investors own 96.77% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.